Printer Friendly

Stalking a vaccine for skin cancer.

Stalking a vaccine for skin cancer

Taking some of the hair of the dog that bit you mab prove sound advice when it comes to skin cancer.

David Berd, an oncologist at Thomas Jefferson University in Philadelphia, injected 24 patients who had metastatic melanoma with pieces of their own tumors coated with the immune-system sensitizing agent dinitrophenyl. This month, at the First International Symposium on Combination Therapies in Washington, D.C., he reported that 14 of the volunteers developed an increased immune response to their cancers.

In an earlier study using uncoated tumor cells, Berd found that five of 40 patients showed significant tumor regression. Despite melanoma's extremely high mortality, one patient is still alive eight years after diagnosis, he says. These studies "provide some basis for optimism" about the prospect of developing a vaccine to boost immune responses to melanoma and possibly other cancers, he conludes.
COPYRIGHT 1991 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:metastatic melanoma
Publication:Science News
Date:Mar 30, 1991
Words:147
Previous Article:Shocking treatment proposed for AIDS.
Next Article:Totally organic electronics.
Topics:


Related Articles
Taking a shot at melanoma.
'Vaccine' spurs immune attack on melanoma.
Waving a red flag against melanoma.
MELANOMA 2001.
Anal Melanoma: An Aggressive Malignancy Masquerading as Hemorrhoids.
Unorthodox strategy: new cancer vaccine may thwart melanoma.
AVAX Technologies Announces Special Protocol Assessment Agreement with FDA for a Phase III Clinical Trial of M-Vax in Metastatic Melanoma.
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma.
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters